After the highs of COVID-19-led to bumper years for biotech and pharma IPOs in 2020 and 2021, there was a steep drop in 2022, followed by a further decline in 2023. Between 2021 and 2023, the biotech IPO market experienced a notable decline as investors grew increasingly cautious due to the uncertainties surrounding the pandemic and economic downturn. According to the Nasdaq Biotechnology Index (NBI), only 21 biotech IPOs were recorded in 2022, a significant decrease compared to the 104 biotech IPOs observed in 2021. Another report highlights that just 38 life science companies went public between 2022 and 2023, compared to 179 across 2020-2021, according to data from Silicon Valley Bank. That's the lowest in a two-year period since 2011-2012.
Bu hikaye BioSpectrum Asia dergisinin June 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin June 2024 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Australia develops AI sperm checker to enhance IVF success
Engineers in Australia have developed an artificial intelligence (AI) technology that accurately assesses the quality of live sperm in seconds, removing the need for invasive procedures that compromise sperm viability in vitro fertilisation (IVF) treatments.
Singapore discovers new fungus type, a possible global public health threat
Researchers from the Singapore General Hospital (SGH), A*STAR’s Genome Institute of Singapore (GIS) and Yong Loo Lin School of Medicine at National University of Singapore (NUS Medicine) have discovered a new clade (or type) of Candida auris, bringing the number of clades known globally to a total of six.
Singapore strengthens focus on computational biology
Singapore's National Quantum Office (NQO), Agency for Science, Technology and Research (A*STAR), National University of Singapore (NUS), National Supercomputing Centre (NSCC) and Quantinuum have signed a Memorandum of Understanding (MoU), enabling access to Quantinuum's advanced quantum computer, and to explore and collaborate on quantum computing use cases, focusing on computational biology.
Global scientists explore innovative tech to rapidly make new vaccine antigens
Researchers in the US are pursuing pioneering technology that may be able to rapidly create safe and effective vaccines against deadly epidemic and pandemic diseases that are more stable and less expensive than current vaccines.
Korea develops micro-structured artificial lung model using bioprinting technology
A team of Korean researchers has made a breakthrough that will greatly enhance the efficiency of respiratory disease research, garnering attention.
Philips names Ling Liu as Chief Region Leader of Greater China
Royal Philips, a global leader in health technology, has announced the appointment of Ling Liu as the Chief Region Leader of Philips Greater China.
PW Skills launches School of Healthcare to solve India's critical shortage of medical professionals
PW Skills, the upskilling vertical of Physics Wallah (PW) has announced the launch of School of Healthcare across five cities in India, namely, Noida, Indore, Lucknow, Patna and Delhi.
Australian biotech incubator Proto Axiom announces $20 M Series B first close
Proto Axiom, the Australian biomedical technology incubator, has announced a $20 million first close of its targeted $30 million Series B, to bolster Australia's biotechnology sector through increased intellectual property (IP) retention.
Biogen, Beckman Coulter and Fujirebio to develop new tests for tau pathology
Biogen Inc., Beckman Coulter, Inc. (both based in the US) and Japan-based Fujirebio have announced a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialise new tests for tau pathology in Alzheimer’s disease (AD).
Pfizer upgrades pharma production plant in Melbourne
Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria.